NCT06212557

Brief Summary

Evaluation of a mobile medical app (KIOS) vs. treatment as usual for the treatment of opioid use disorder (OUD).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
210

participants targeted

Target at P75+ for not_applicable

Timeline
0mo left

Started May 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress97%
May 2024May 2026

First Submitted

Initial submission to the registry

January 8, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 19, 2024

Completed
3 months until next milestone

Study Start

First participant enrolled

May 2, 2024

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2026

Expected
Last Updated

April 10, 2025

Status Verified

April 1, 2025

Enrollment Period

1.7 years

First QC Date

January 8, 2024

Last Update Submit

April 7, 2025

Conditions

Keywords

Digital health therapeuticBehavioral intervention strategiesClinic-based counseling

Outcome Measures

Primary Outcomes (1)

  • Retention in treatment

    Measured by the number of days from the start of the 13-week intervention until the participant either leaves the trial, or completes the trial

    Baseline to 13 weeks

Secondary Outcomes (5)

  • Measure of opioid use reduction

    60 days to 13 weeks

  • Percentage of Opioid Abstinent Days

    Baseline to 13 weeks

  • Completion of treatment

    Baseline to 13 weeks

  • Patient Health Questionnaire-9 (PHQ-9)

    Baseline and 13 weeks

  • Treatment Effectiveness Assessment TEA)

    Baseline and 13 weeks

Study Arms (2)

Active Treatment as Usual plus KIOS App

EXPERIMENTAL

Treatment as usual in clinics with the use of the KIOS App

Device: KIOS AppBehavioral: Treatment as usual

Treatment as Usual plus KIOS education App

SHAM COMPARATOR

Treatment as usual in clinics with the use of the KIOs education App (Sham)

Behavioral: KIOS App educationBehavioral: Treatment as usual

Interventions

KIOS AppDEVICE

KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during Medication-Assisted Treatment (MAT)

Also known as: KIOS
Active Treatment as Usual plus KIOS App

Educational tools provided to participants with opioid use disorder

Also known as: KIOS education
Treatment as Usual plus KIOS education App

Behavioral counseling in clinic

Also known as: TAU
Active Treatment as Usual plus KIOS AppTreatment as Usual plus KIOS education App

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female outpatients 18 years of age or older
  • Patients must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
  • DSM-5 (Diagnostic and Statistical Manual of Mental Disorders fifth edition) criteria for opioid use disorder
  • Ability to access KIOS via smartphone or tablet
  • Recently (less than 6 months) enrolled in and currently participating in MOUD at a clinic in Texas

You may not qualify if:

  • Unwilling or unable to comply with study requirements
  • Psychiatric or medical disorder interfering with ability to use the app
  • Incarceration

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Texas Health Science Center - Department of Psychiatry

San Antonio, Texas, 78229, United States

RECRUITING

MeSH Terms

Conditions

Opioid-Related Disorders

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Study Officials

  • Jennifer Potter, PhD, MPH

    The University of Texas Health Science Center at San Antonio

    PRINCIPAL INVESTIGATOR
  • Elise Marino, PhD

    The University of Texas Health Science Center at San Antonio

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jennifer Potter, PhD, MPH

CONTACT

Elise Marino, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Masking Details
Randomization will be stratified by two characteristics: (1) history of MOUD and (2) stimulant use in past one month. Allocation to treatment groups will be randomly assigned by 1:1 allotment to either KIOS + TAU (treatment as usual) or KIOS sham + TAU with strata. Study staff will be blind to the condition to which the participant is assigned.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized controlled 2 arm trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 8, 2024

First Posted

January 19, 2024

Study Start

May 2, 2024

Primary Completion

December 31, 2025

Study Completion (Estimated)

May 31, 2026

Last Updated

April 10, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will share

This study will be conducted in accordance with the following publication and data sharing policies and regulations: National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access to the published results of NIH funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication. This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer-reviewed journals.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
After study completion and data analysis when summary results are posted on ClinicalTrials.gov and then after peer review and publication acceptance.

Locations